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1. Introduction
Incidence of melanoma is steadily rising worldwide [1]. Lifetime risk of developing melano‐
ma in Caucasians is estimated as 1 in 50 individuals [2-3]. The incidence of melanoma varies
according to the geographical origins of the population and the extent of sun exposure. In
Australia and United States, an incidence of melanoma higher than observed in the Europe‐
an countries (with the notable exception of Sweden) has been reported [4-5]. There is a gra‐
dient of melanoma incidence from north to south in Europe, with highest frequencies in the
northern counties. This suggests that initiation and development of melanoma is due to a
combination of the damaging effects of UV and a predisposing genetic background [5].
Melanoma arises from melanocytes, neural crest-derived cells that are located in the basal
layer of the epidermis and skin appendages in humans. Melanocytes, by synthesizing mela‐
nin pigments and exporting them to adjacent keratonocytes play a key role in protecting the
skin from the damaging effects of ultraviolet (UV) and other solar radiation [6]. Melanocytes
can proliferate to form nevi (common moles), initially in the basal epidermis (junctional ne‐
vus) and later by limited local dermal infiltration (compound nevus). Nevi develop during
embryonic life (congenital nevus) and in children and adults, (acquired nevus) partly as a
result of solar exposure in the latter two populations. Further progression of melanocytic tu‐
mors relates to factors that include intermittent exposure to UV radiation (though a direct
relationship between risk of melanoma and UV exposure remains somehow unclear), a his‐
tory of sunburn and endogenous factors such as skin type and elevated numbers of nevi (es‐
pecially dysplastic nevi, also known as atypical moles) [7-8].
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Considering the growth patterns, four histological types of melanoma have been historically
recognized: superficial spreading melanoma (SSM), lentigo maligna melanoma (LMM), nod‐
ular melanoma (NM), and acral lentiginous melanoma (ALM) [9]. Comparative genomic hy‐
bridization revealed that several genomic regions (mostly, 11q13, 22q11-13, and 5p15) were
abnormally amplified in ALM [10]; such regions were different from those found altered in
superficial SSM or NM (mainly, 9p21 and 1p22) [11]. Recently, a new classification of mela‐
noma including the site of primary tumour and the degree of chronic sun-induced damage
of the surrounding skin has been introduced [12]. Based on these criteria, melanomas are
classified into four groups; melanoma on skin with chronic sun-damage (CSD melanoma),
melanoma on skin without chronic sun-damage (non-CSD melanoma), melanoma on palms,
soles and nail bed (acral melanoma), and melanoma on mucous membrane (mucosal mela‐
noma) [12]. Non-CSD melanomas are characterized by high frequency of BRAF or NRAS
mutations (which are mutually exclusive), while CSD, acral, and mucosal melanomas show
a low frequency of BRAF/NRAS mutations but a high incidence of alterations in additional
genes, such as mutations of receptor tyrosine kinase KIT gene, amplifications of cyclin D1
(CCND1) and cyclin-dependent kinase 4 (CDK4) genes [7, 12-13]. All genes affected into the
different types of melanoma are involved in regulating cell-cycle progression and cell sur‐
vival [12-13]. On the other hand, such a difference of genetic alterations indicates distinct ge‐
netic pathways in the pathogenesis of melanoma depending on the anatomical site of the
primary lesion. Trying to merge the two classifications, it could be affirmed that non-CSD
melanoma roughly corresponds to SSM, CSD melanoma to LMM, and acral melanoma to
ALM. Since NM may arise at any anatomical site, this histological type can not be included
in any of the subgroups of the latter classification (indeed, no distinct genetic pathway has
been so far correlated with NM).
During recent past years, melanocytic transformation is being demonstrated to occur as a
sequential accumulation of genetic and molecular alterations [13-14]. In this sense, it is be‐
coming  an  unquestionable  certainty  that  molecular  classification  of  melanoma  patients
could  be  achieved  through  the  assessment  of  the  molecular  profile  of  primary  tumors
and/or the correspondent metastases, by unveiling which gene or pathway is truly affect‐
ed. Although pathogenetic mechanisms underlying melanoma development are still large‐
ly unknown, several genes and metabolic pathways have been shown to carry molecular
alterations in melanoma.
2. Main genes and related pathways
2.1. BRAF and MAPK pathway
The mitogen-activated protein kinase (MAPK) signal transduction pathway regulates cell
growth, survival, and invasion. MAPK signaling is initiated at the cell membrane, either by
receptor tyrosine kinases (RTKs) binding ligand or integrin adhesion to extracellular matrix,
which transmits activation signals via RAS on the cell membrane inner surface (Figure 1).
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Figure 1. Main pathways involved in melanomagenesis. Arrows, activation signals. Interrupted lines, inhibition signals.
RAS proteins are small GTPases thatare activated by extracellular stimuli and regulate sig‐
nal transduction of the BRAF-MEK1/2-ERK1/2 and AKT/PI3K pathways, controlling crucial
cellular processes such as proliferation, differentiation, cell adhesion, apoptosis, and cell mi‐
gration [14-16]. RAS gene is mutated in an estimated 20-30% of all cancers [17]. RAS proteins
are constituted by three main isoforms - NRAS, KRAS, and HRAS, which present a similar
function but a different specificity for tissue distribution [18]. On this regard, KRAS altera‐
tions mostly occur in gastrointestinal cancer [17-18], HRAS alterations are frequently ob‐
served in bladder cancer, and NRAS is mutated in 15-25% of melanomas [17-18]. Despite the
huge amount of knowledge implicating RAS in tumour initiation and promotion, RAS itself
has not become a successful target of therapy.
The RAF kinase family consists of three members - ARAF, BRAF, and CRAF, all of which
can activate a series of protein kinases; such a signaling cascade culminate in the phosphory‐
lation and activation of the extracellular signal-regulated kinase (ERK) downstream protein
[19]. In melanoma, the most commonly mutated component of this pathway is the BRAF
gene; the prevalent BRAF mutation (in nearly, 90% of cases) being a substitution of valine
with glutamic acid at position 600 (V600E) [20]. Mutated BRAF induces constitutive ERK ac‐
tivation; activated ERK then translocates to the nucleus and initiates the transcription of a
variety of growth-related genes, stimulating cell proliferation and survival [20]. Indeed, the
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increased activity of ERK seems to be implicated in rapid melanoma cell growth, enhanced
cell survival and resistance to apoptosis [21]. High levels of activated ERK may further in‐
duce the metastatic potential of melanoma by increasing the expression of invasion-promot‐
ing integrins [22-23]. Presence of BRAF mutations in benign and dysplastic nevi supports
the hypothesis that activation of the RAF/MEK/ERK pathway is an early event in melanoma
progression [24-25]. In other words, BRAF activation is necessary but not sufficient for the
development of melanoma and additional co-operating genetic events are required to ach‐
ieve full malignancy.
In a study aimed to better define the role of BRAF in melanomagenesis, a transgenic zebra
fish expressing V600EBRAF showed dramatic development of patches of ectopic melanocytes
(designated as fish-nevi) [26]. Remarkably, activated BRAF in p53-deficient zebra fish in‐
duced the formation of melanocytic lesions that rapidly developed into invasive melanomas
that resembled human melanomas in terms of their histology and biological behaviors [26].
These data provide direct evidence that the p53 and BRAF pathways interact functionally
during melanomagenesis.
The BRAF gene also cooperates with the cyclin-dependent kinase inhibitor p16CDKN2A (see be‐
low). Activating BRAF mutations have been reported to constitutively induce up-regulation
of p16CDKN2A and cell cycle arrest (this phenomenon appears to be a protective response to an
inappropriate mitogenic signal). In particular, mutant BRAF protein induces cell senescence
by increasing the expression levels of the p16CDKN2A protein, which, in turn, may limit hyper‐
plastic growth caused by BRAF mutations [25]. Therefore, inactivation of p16CDKN2A gene
may promote the melanocytic proliferation depending on oncogenic BRAF. In this sense,
several factors seem to be able to induce the arrest of the cell cycle and cell senescence
caused by BRAF activation [27-28].
Finally, it has been showed that primary melanomas arising from chronically sun-damages
skin and from mucosal sites, which typically do not harbour BRAF and NRAS mutations,
have increased copy number of the CCND1/Cyclin D1 gene [12]. In contrast to primary mela‐
nomas, a subset (>15%) of metastatic melanoma samples with BRAF mutations also exhibit
amplification of CCND1/Cyclin D1. These melanomas are resistant to BRAF inhibitors high‐
lighting the need for combination therapy [29-30].
2.2. CDKN2A and senescence/apoptosis pathways
The  cyclin-dependent  kinase  inhibitor  2  (CDKN2A;  at  chromosome  9p21)  gene  encodes
two  proteins,  p16CDKN2A  and  p14CDKN2A  (a  product  of  an  alternative  splicing),  that  are
known to function as tumor suppressors [31-33]. The cyclin proteins are regulatory effec‐
tors able to bind and activate the cyclin-dependent kinases (CDKs) that bear catalytic kin‐
ase activity. Several distinct cyclin/CDK complexes have been identified and functionally
assigned to  specific  phases  of  the  cell  cycle:  Cyclin  D/CDK4 complex leads the passage
from the pre-replicative (G1) to the DNA duplication (S) phase; the Cyclin E/CDK2 com‐
plex promotes the progression through the S phase and the Cyclin B/CDK1 complex indu‐
ces cells to enter mitosis [31-32]. In such a functional network, proteins like p16CDKN2A and
p14CDKN2A  act as inhibitors of the cell cycle, negatively interfering with the activity of the
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cyclin/CDK complexes and, in this way, ensuring the control of the cell replication [33]. In
particular, p16CDKN2A is part of the G1–S cell cycle checkpoint mechanism that involves the
retinoblastoma-susceptibility  tumor  suppressor  protein  (pRb).  The  p16CDKN2A  inhibits  the
Cyclin  D/CDK4  complex,  which,  in  turn,  phosphorylates  pRb  and  allows  progression
through the G1–S checkpoint (Figure 1) [33]. The Cyclin D (CCND1) and CDK4 genes are
found  altered  in  less  than  5%  of  total  melanomas  [12],  though  with  an  heterogeneous
prevalence according to the distinct types of melanoma (see above). Somatic CDK4 ampli‐
fication  is  relatively  common  in  acral  and  mucosal  melanomas  [12],  whereas  germline
CDK4  mutations are observed in a limited fraction of melanoma-prone families [34]. The
CCND1  gene amplifications is  primarily  found in ALM lesions (more than one third of
cases) and to a lesser degree in other types (11% for LMM and 6% for SSM) [35]. Regard‐
ing the alternative CDKN2A gene product, p14CDKN2A  is an antagonist of the murine dou‐
ble  minute  2  (MDM2)  protein,  which  targets  p53  to  degradation  by  ubiquitination  and
proteasome processing,  thus abrogating p53 control  of  cell  growth (Figure 1)  [32-33].  In
particular,  the p14CDKN2A  protein exerts a tumor suppressor effect by inhibiting the onco‐
genic actions of the downstream MDM2 protein, whose direct interaction with p53 blocks
any p53-mediated activity and targets the p53 protein for rapid degradation [32-33]. The
p53 is a transcription factor that functions as a major negative regulator of cell prolifera‐
tion and survival,  being activated by different  adverse signals  (i.e.  growth factors  with‐
drawal,  DNA  damage,  oncogenic  aberrations,  hypoxia,  etc.)  and  driving  cells  to  either
interrupt progression into the cell-cycle or enter apoptosis program, in order to avoid re‐
production of altered cells [33, 36]. In normal conditions, expression levels of p53 within
cells  are low. In response to DNA damage,  p53 accumulates and prevents cell  division.
Therefore, inactivation of the TP53 gene results in an intracellular accumulation of genetic
damage which promotes tumor formation [36]. In melanoma, such an inactivation is most‐
ly due to functional gene silencing since the frequency of TP53 mutations is low (less than
10% of cases) [37]. Impairment of the p14CDKN2A-MDM2-p53 cascade, whose final effectors
are the Bax/Bcl-2 proteins, has been implicated in defective apoptotic responses to geno‐
toxic damage and, thus, to anticancer agents (in most cases, high expression levels of Bcl-2
protein have been demonstrated to reduce apoptosis and sensitivity of melanoma cells to
proapoptotic stimuli, contributing to further increase tumor aggressiveness and refractori‐
ness to therapy) [33].
More in general,  genetic loss or rearrangement in the CDKN2A locus may result  in im‐
pairing or silencing p16CDKN2A, p14CDKN2A or both genes, with the consequence of losing the
mechanisms  controlling  cell  proliferation  and/or  survival.  In  melanoma,  the  CDKN2A
gene  is  somatically  inactivated  by  genomic  deletions  (approximately  50%  of  cases)  or
point mutations (about 10% of cases);  in addition,  this gene is  often transcriptionally si‐
lenced by promoter hypermethylation [38]. A reduced expression of the p16CDKN2A protein
seems to be strictly associated with malignant tumor invasion, varying from 5% to about
15% in benign melanocytic  lesions,  from 10% to about 50% in primary melanomas,  and
from 50% to  about  60% in  melanoma metastases  [39].  The  CDKN2A  gene  is  frequently
mutated at germline level in patients with a strong familial history of melanoma (three or
more affected family members), indicating that it represents a key susceptibility gene for
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familial melanoma [40]. In melanoma, CDKN2A mutations typically occur in the p16CDKN2A
gene, either alone or in combination with p14CDKN2A  gene (some families harbor however
mutations only in this latter gene) [33, 40].
A recent meta-analysis of studies conducted in independent populations indicated that mul‐
tiple variants of the melanocortin-1 receptor (MC1R) gene increase the melanoma risk in
CDKN2A mutation carriers [41]. The MC1R gene encodes a G-protein coupled receptor. In
the skin, two types of melanin pigment, dark-protective eumelanin and red-photo reactive
pheomelanin, are present [42]. MC1R plays an important role in determining the ratio of eu‐
melanin and pheomelanin production. After stimulation by UV, keratinocytes produce al‐
pha melanocyte stimulating hormone (MSH) that binds to the MC1R on melanocytes and
shifts the balance of these two pigments in the direction of eumelanin [42]. In particular,
stimulation of MC1R by MSH mediates activation of adenylate cyclase, subsequent eleva‐
tion of cAMP levels, and activation of the microphthalmia transcription factor (MITF; see be‐
low). Activated MITF binds to a conserved region found in the promoters of the tyrosinase
(TYR), tyrosinase-related protein 1 (TYRP1), and DOPAchrome tautomerase (DCT) genes, stimu‐
lating the transcriptional up-regulation of these proteins and inducing maturation of the
melanosomes [43]. This ultimately results in increased eumelanin production and darkening
of the skin or hair.
New findings have shed light on the mechanisms by which MC1R contributes to melanoma
risk. In vitro studies showed that acute UV irradiation of melanocytes with impaired MC1R
results in an increased production of free radicals [44]. Melanomas that arise on body sites
only intermittently exposed to sun, and which therefore lack marked signs of chronic solar
damage, were found to have a high frequency of BRAF mutations [12]. One could speculate
that induction of BRAF mutations may occur only when solar exposure is not sufficiently
prolonged to induce the striking tissue changes that generate the hallmark signs of solar
damage. Several MC1R variants, that impairing relevant protein function, have been associ‐
ated with BRAF mutation in melanoma arising in Caucasian populations from United States
and Europe [45-48]. On the basis of such indications, it is possible that increased production
of free radicals following UV exposure is combination with impairment of MC1R may in‐
duce mutations in the BRAF gene.
Additional mechanisms promoting susceptibility to pathogenetic mutations of the BRAF
gene may however exist since there is no demonstrable association between germ line MC1R
status and the prevalence of somatic BRAF mutations in melanomas from Australian popu‐
lation, even after classifying the melanomas by their location relative to intermittent and
chronic sun-exposure [49].
2.3. PTEN and mTORC pathways
Phosphatase and tensin homolog deleted in chromosome ten (PTEN) has a key role in cellu‐
lar signal transduction by decreasing intracellular phosphatidylinositol [3,4-bisphosphate
(PIP2) and 3,4,5-triphosphate (PIP3)] that are produced by the activation of phoshoinosite 3-
kinase (PI3K) [50]. In the absence of extracellular growth stimuli mediated by cell surface re‐
ceptors and G-proteins, PTEN dephosphorylates PIP3 generating the PIP2 phospholipid,
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unable to stimulate phosphorylation of the PI3K protein; this in turn maintains suppression
of cell cycle progression and cell growth. In other words, there is a balance between PIP2
and PIP3 which is maintained by the opposite activities of PTEN and PI3K, which instead
converts PIP2 into PIP3 [50]. Upon growth stimulation, mainly obtained by triggering the
RAS kinase, PI3K is constitutively activated (Figure 1), resulting in an increase of intracellu‐
lar levels of PIP3 and a consequent activation of AKT by phosphorylation [50-51]. Activated
AKT in turn phosphorylates its substrate, the serine/threonine kinase mTOR, leading to in‐
creased synthesis of target proteins that promote cell division and survival as well as apop‐
totic escape [51]. The mechanisms associated with the ability of AKT to suppress apoptosis
include the phosphorylation and inactivation of many pro-apoptotic proteins, such as BAD
(Bcl-2 antagonist of cell death) and MDM2, as well as the activation of NF-kB [52] (Figure 1).
Three AKT genes have been described in humans: AKT1, which is involved in apoptosis and
protein synthesis; AKT2, which is involved in controlling the glucose metabolism; and
AKT3, whose increased activity (often associated with the amplification of the AKT3 locus at
chromosome 1q43-44) is mainly involved in stimulating cell growth and has been implicated
in many cancers including melanoma [51-52]. More than two thirds of primary and meta‐
static melanomas exhibit higher levels of phosphorylated AKT [52], suggesting that such an
alteration might be considered as an early event in melanoma pathogenesis.
Overall,  PI3K  expression  is  higher  in  malignant  melanomas,  as  compared  to  nevi,  and
seems to  correlate  with a  worse prognosis  [53].  In  primary melanomas,  since activating
mutations of PI3K are quite rare (about 1%), and comparative genomic hybridization did
not reveal amplification at this gene locus [12, 37], activation of the PI3K pathway is most‐
ly due to functional silencing of the tumour suppressor gene PTEN. Inactivation of PTEN
gene is  mainly  due to  hypermethylation-based epigenetic  mechanisms,  with  a  low inci‐
dence (less than 10%) of  somatic  mutations and/or allelic  deletions;  loss of  (or reduced)
PTEN  protein  is  observed  by  immunohistochemistry  in  20-40%  of  melanoma  tissues
[54-55]. Consistent with its role in the PI3K-AKT pathway, vast majority (more than 80%)
of melanoma samples with loss of PTEN protein presents a significant increase in expres‐
sion of phosphorylated AKT [37].
PTEN inactivation has been mostly observed as a late event in melanoma, although a dose-
dependent down-regulation of PTEN expression has been implicated in early stages of tu‐
morigenesis, often occurring in conjunction with mutations in BRAF gene (which have been
demonstrated to indeed play a role in induction of the melanocytic proliferation and early
steps of melanoma development) [50]. PTEN downregulation In addition, alterations of the
BRAF-MAPK pathway are frequently associated with PTEN-AKT impairment [7, 56]. In
summary, the combined effects of the inactivation of PTEN gene and activation of the PI3K-
AKT effectors may result in aberrant cell growth, apoptosis escape, and abnormal cell
spreading and migration [33, 50].
2.4. MITF and melanocytic differentiation
The microphthalmia-associated transcription factor (MITF) is a transcription factor that is in‐
volved in differentiation and maintenance of melanocytes, playing a role in melanoma de‐
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velopment and pathogenesis [43, 57]. MITF is activated by the MAPK pathway as well as by
the cAMP pathway (Figure 1), and leads to transcription of genes involved in pigmentation
(TYR, TYRP1, and DCT; see above) as well as cell cycle progression and survival [43]. The
MITF gene is amplified in melanoma (about 20% of cases); MITF amplification correlated
with increased resistance to chemotherapy and decreased overall survival [57].
The connection between MITF and melanoma development is complex because it plays a
double role of inducer/repressor of cellular proliferation. High levels of MITF expression
lead to G1 cell-cycle arrest and differentiation, through induction of the cell cycle inhibitors
p16CDKN2A and p21 [58-59] (Figure 1). Very low or null MITF expression levels predispose to
apoptosis whereas inter-mediate MITF expression levels promote cell proliferation [57-59].
Therefore, it is thought that melanoma cells have developed strategies to maintain MITF lev‐
els in the range compatible with tumorigenesis. It has been shown that constitutive ERK ac‐
tivity, stimulated by V600EBRAF in melanoma cells, is associated with MITF ubiquitin-
dependent degradation [60]. Nevertheless, continued expression of MITF is necessary for
proliferation and survival of melanoma cells, because it also regulates CDK2 and Bcl-2 genes
[61-62]. It has been recently shown that oncogenic BRAF may control intracellular levels of
the MITF protein through a fine balance of two opposite mechanisms: a direct reduction of
MITF levels, by inducing protein degradation, and an indirect increase of MITF levels, by
stimulating transcription factors which increase protein expression levels [63]. Oncogenic
BRAF mutations are associated with MITF amplification in a low fraction (10-15%) of mela‐
nomas [63], suggesting that other mechanisms are likely to be involved in ERK-dependent
degradation of MITF.
2.5. iNOS and NF-kB pathways
Human melanoma cells are known to express the inducible nitric oxide synthase (iNOS)
enzyme, which is responsible for synthesis of nitric oxide (NO), a free radical involved in
several physiological processes such as neurotransmission, vasodilation, and regulation of
immune responses [64]. The iNOS enzyme has been found to be frequently expressed in
melanoma [65-66] and the subsequent increased concentrations of NO have been demon‐
strated to  contribute  to  melanomagenesis  through a  sustained protection of  the  tumour
from apoptosis [67]. However, the role of iNOS in melanoma progression remains contro‐
versial. Higher levels of iNOS have been found in subcutaneous and lymph node metasta‐
ses  of  non-progressive  melanoma  as  compared  to  metastases  of  progressive  melanoma
[68],  however, iNOS was found to be expressed to a lesser extent in metastases as com‐
pared with nevi and primary melanomas [69]. Nevertheless, the expression of iNOS in pa‐
tients with lymph nodes and in-transit metastases (stage III disease) has been proposed as
an indicator of poor prognosis [70].
Recently,  it  has  been  reported  that  the  constitutive  iNOS expression  in  melanoma cells
might be induced by activation of the MAPK pathway through stimulation of the activity
of the Nuclear Factor-kB (NF-kB) [71-72]. NF-kB is a protein complex that acts as a tran‐
scriptional factor and regulates the transcription of several genes involved in many critical
pathways [73]. In a quiescent status, proteins of the NF-kB complex are localized into the
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cytoplasm. NF-κB exists as cytoplasmic hetero- or homodimers associated with members
of the inhibitor-of-kB (IkB) proteins (IkBa, IkBb and IkBe), which form complexes seques‐
tering NF-kB into the cytoplasm [74]. Upon appropriate stimulation, the phosphorylation
of IkB proteins is promoted, triggering their ubiquitination and degradation in the protea‐
some [74]. As a consequence, NF-kB may translocate to the nucleus where it binds to tar‐
get  DNA loci  and  induces  transcription  of  several  genes  -  including  iNOS  -  associated
with immune and inflammatory response, angiogenesis,  cell  proliferation, tumor promo‐
tion, and apoptosis [73-74].
Regarding the role of NF-kB in tumorigenesis, there are compelling evidence that activation
of NF-kB controls multiple cellular processes in cancer due to its ability to promote cell pro‐
liferation, suppress apoptosis, promote cell migration, and suppress cell differentiation,
opening the way for new therapeutic approaches against such a target [75-76]. In melanoma,
NF-kB is constitutively activated since expression of the IkB proteins seems to be significant‐
ly reduced in comparison to nevi [77].
2.6. cKIT and tyrosinase kinase receptors
cKIT is a member of the transmenbrane receptor tyrosine kinase family that comprised five
immunoglobin-like motifs, a single transmembrane region, an inhibitory cytoplasmic juxta‐
menbrane domain, and a split cytoplasmic kinase domain separated by a kinase insert seg‐
ment [78]. Under physiological conditions, binding of the cKIT ligand stem-cell factor (SCF)
to the extracellular domain of the receptor leads its dimerization, activation of the intracellu‐
lar tyrosine kinase domain through autophosporylation of specific tyrosine residue [78]. The
intracellular signaling through cKIT plays a critical role in the development of several mam‐
malian cells, including growth, differentiation, migration, and proliferation of melanocytes
[79]. It has been defined that cKIT recruits and activates a number of intracellular signaling
pathways implicated in tumor progression, such as MAPK, PI3K/AKT, Src, activators of
transcription (STAT), and phospholipase-C (PLC) [79-80].
Although the role of cKIT in melanomagenesis is still  controversial,  several studies have
reported its  downregulation during melanoma growth and invasion (in  vertical  growth
phase of melanoma and metastatic lesions) [81-83].  Indeed, the majority of highly meta‐
static human melanomas do not express detectable levels of the cKIT receptor [83]. As a
confirmation of this, over-expression of cKIT in metastatic melanoma cell lines led to im‐
portant  reduction  in  tumor  growth,  while  cKIT activation  through exposure  to  cKIT li‐
gands induced apoptosis [83].
Specific mutations within the cKIT gene cause constitutive phosphorylation and activation
of the kinase domain resulting in uncontrolled cell proliferation. [84]. Although such muta‐
tions seem to be more rare than BRAF and NRAS mutations, these may reflect the important
role of cKIT tyrosine kinase in melanocyte development [84]. Sequencing of cKIT exons 11,
13, 17, and 18 revealed the most prevalent mutation to be K642, L576P, D816H-V, V559A
[84]. The cKIT mutations are more common in mucosal and acral melanomas compared
with cutaneous melanomas and are in most cases accompanied by an increase in gene copy
number (40% mucosal or acral melanomas - frequently, associated with amplification of cy‐
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clin D1 - as well as 30% of melanomas on skin with chronic sun-induced damage) [84]. High
expression levels of cKIT and CDK4 proteins have been identified in another subset of mela‐
nomas lacking BRAF mutations [85].
2.7. CTLA-4 and T-cell activation
The above-mentioned main intracellular molecular pathways are thus involved in tumor
growth and survival, actively participating to the different phases of development and progres‐
sion of melanoma. Additional extracellular factors, mainly represented by different compo‐
nents of the tumor microenvironment, have been implied to play a role in melanoma tissue
invasion and metastatic dissemination. As an example, changes in the expression of adhesion
molecules such as MCAM/MUC18, E-cadherin, and integrins occur in the transition from the ra‐
dial growth phase (RGP) to the vertical growth phase (VGP) of melanoma; they are induced by
both intracellular modifications [i.e., activation of the focal adhesion kinase (FAK) and integrin
linked kinase (ILK) patways or high levels of activated ERK (phospoERK1-2)] and biological sig‐
nals directly generated by the extracellular matrix (ECM), which is composed of proteins, glyco‐
proteins, proteoglycans, and glycosaminoglycans in complex arrangements [22-23].
Among others, a block of the anti-tumor immune response induced by changes in pericellular
microenvironment has been demonstrated to contribute to melanoma progression [86]. In re‐
cent past years, research has tried to better define the molecular mechanisms underlying the
downregulation of the immune system by such pericellular components, in order to develop
new therapeutic targets [87]. Actually, two immunomodulant antibodies, such as anti-CTLA4
and anti-PD1, have been demonstrated to be effective in inhibiting some down-regulators of the
anti-tumor immune response [30, 88]. Moreover, drugs able to interfere with the differentiation
of the myeloid-derived suppressor cells (MDSC) and T regulatory cells (Treg), which are both
physiologically involved in controlling an abnormal immune response during the inflammato‐
ry processes and pathologically favoring tumor progression through suppression of T-cell acti‐
vation, represent additional therapeutic strategies to be exploited [89].
For T-cell activation, melanoma antigens that are bound to the major histocompatibility com‐
plex (MHC) on antigen-presenting cells (APCs) require the costimulation of CD28 receptor on T-
cells by CD80 or CD86 ligands on APCs [90]. The cytotoxic T-lymphocyte antigen-4 (CTLA-4)
can bind with greater affinity to CD80 and CD86, and thus disrupt the necessary costimulatory
signal provided by APCs [88, 90]. This led to the hypothesis that blockade of CTLA-4 function
may allow for optimal costimulation of CD28 receptors on T-cells by APC CD80/86, and en‐
hanced T-cell activation [88, 90]. Ipilimumab (Yervoy™ Bristol-Myers Squibb, New York, NY)
blocks the costimulatory signal required for T-cell activation [30, 88]. In particular, Ipilimumab
is a recombinant human IgG1 monoclonal antibody that binds to CTLA-4 and blocks binding to
CD80 or CD86 on APCs, thus increasing activation and proliferation of T cells [88]. Two random‐
ized phase III trials have indicated a significant advantage in disease-free survival (DFS) and
overall survival (OS) in either monotherapy or combination therapy [91-92]. The first trial com‐
pared monotherapy with Ipilimumab 3 mg/kg, combination of Ipilimumab with gp100 vaccine,
and gp100 vaccine alone; the study demonstrated a significant advantage in OS for patients
treated with Ipilimumab (regardless the addition off gp100) in comparison to those receiving the
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gp100 vaccine alone [median OS 10.0 vs 6.4 mesi; Hazard Ratio (HR) for death, 0.68; p<0,001)
[91]. In the second study, Dacarbazine was administered as standard chemotherapeutic drug for
melanoma patients, in association with Ipilimumab or placebo; the OS rate was significantly
higher in the group of patients treated with Ipilimumab + Dacarbazine (11.2 vs. 9.1 months), with
even more significant percentages of survival for such an association after one year (47.3% vs.
36.3%), two years (28.5% vs. 17.9%), or three years (20.8% vs. 12.2%) of follow-up [92]. The DFS
and OS curves from the two studies have been indicated as largely overlapping, strongly dem‐
onstrating, for the first time in the history of medical treatments for the advanced disease, a clear
survival benefit in metastatic (disease stage IV) melanoma. For these reasons, Ipilimumab has
been recently approved by FDA and EMEA for the treatment of metastatic melanoma.
3. Melanoma subtypes and targeted therapeutic options
The different molecular pathways involved into the pathogenesis of melanoma are function‐
ally linked each other (Figure 1). There is thus a need to consider such biological cascades as
part of a functional web, and the alterations detected in distinct components of the various
pathways must be globally considered for the effects determining in such a functional web.
This new vision helps in clarifying the reasons by which some alterations may coexist or not
in specific melanoma subtypes. As an example, BRAF mutations may be observed in con‐
junction with PI3K alterations, but none of them may coexist with NRAS mutations; since
BRAF and PI3K kinases act downstream NRAS protein, occurrence of NRAS mutations acti‐
vating both MAPK and PI3K-AKT pathways makes unnecessary the further activation of
BRAF and PI3K (upstream effectors of the MAPK and PI3K-AKT pathways, respectively).
Analogously, oncogenic BRAF mutations are able to more intensively activate ERK protein,
main last effector downstream the MAPK pathway, when inactivation of the mechanisms
controlling senescence and apoptosis concomitantly occurs.
In an attempt to simplify such complex processes underlying the different phases of devel‐
opment and progression of melanoma, the main pathogenetic molecular alterations may be
grouped in the following way:
• oncogenic BRAF mutations, genomic rearrangements (mainly represented by allelic dele‐
tions) at the 9p21 chromosome, and increased expression levels of the AKT3 protein are
the main alterations involved into the phase of stimulation of the proliferation for normal
melanocytes (initial preneoplastic phase);
• impairments of the mechanisms controlling the cell senescence, apoptosis and cell surviv‐
al (which particularly include alterations in the different components of CDKN2A path‐
ways: functional deficit of p16CDKN2A gene, amplification of CDK4-Cyclin D1/CCND1 loci,
inattivation of TP53 gene through a deregulation of the p14CDKN2A-MDM2-p53 functional
cascade), oncogenic mutations in NRAS gene, activating mutations and, to a lesser extent,
gene amplifications of cKIT are the main alterations involved into the phase of acquisition
of the malignant phenotype which underlay the development of melanoma (intermediate
neoplastic phase);
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• complete silencing of p16CDKN2A gene, functional loss of PTEN, activation of the PI3K-AKT
pathway, and amplification of the MITF gene are the main alterations involved into the
phase of acquisition of a more aggressive and invasive phenotype which underlay the
progression and dissemination of melanoma (final metasticase phase).
All these findings clearly indicate the existence of a complex molecular machinery that pro‐
vides checks and balances in normal melanocytes, allowing a physiologically controlled cell
proliferation. Progression from normal melanocytes to malignant metastatic cell in melano‐
ma patients is the result of a combination of down- or up-regulations of the various effectors
acting into the different molecular pathways. According to this, it has been proposed a line‐
ar model of pathogenesis of melanoma based on the sequential accumulation of most of the
previously-described molecular alterations (Figure 2A) [7, 13, 93]. In a limited fraction of
cases, it has been recently hypothesized a second non-linear model of melanomagenesis
based on accumulation of the same genetic alterations in tissue stem cells, with generation of
malignant cells directly forming RGP or VGP or metastatic melanoma lesions (Figure 2B)
[94]. This latter hypothesis has been derived by the evidence of some inconsistencies of the
linear model in subgroups of melanomas (i.e., incidence of BRAF mutations higher in VGP
lesions than that found in RGP lesions [94]).
Figure 2. Models of development and progression for melanoma. A, sequential model. B, non-linear model.
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Nevertheless, all these evidence represent a strong indication that the different molecular
pathways associated with the melanomagenesis does correspond to different subsets of mel‐
anoma patients, with distinguished biological and clinical behavior of the disease. Identifica‐
tion of such different patients’ subsets should be introduced in clinical trials, in order to
better assess the classification of all predictive and prognostic factors associated with the
disease as well as more accurately address patients to the most effective therapeutic inter‐
vention according to their biological and molecular status.
On the basis of the presence of the specific molecular features, a discrimination of the main
subtypes of melanoma, along with the more appropriate therapeutic option for each sub‐
type, could be schematically reported.
1. Subtype MAPK
Prevalence of BRAF mutations, with tendency to increased expression level of activated ERK
(phospoERK1-2) in melanoma tissues. This subtype benefits by the treatment with inhibitors
of BRAF.
After failure of BAY 43-9006 (which is not specific for mutated BRAF, but suppresses activi‐
ty of several different kinases [95]), a second generation BRAF inhibitor (Vemurafenib, also
known as PLX4032 or RO5185426) was highly specific for V600EBRAF mutation and appeared
very promising from the clinical point of view [96]. Very recently, results from a phase III
study comparing the vemurafenib to dacarbazine have been indeed reported, indicating a
relative reduction of 63% in the risk of death and of 74% in the risk of either death or disease
progression, as compared with dacarbazine [97]. Preliminary data using an additional
V600EBRAF inhibitor compound, Dabrafenib (previously known as GSK2118436), seemed to
point out that this molecule is also active on V600KBRAF and V600DBRAF mutations [98]; actual‐
ly, treatment with such a compound is under evaluation in a phase III study among BRAF
mutation positive stage III-IV melanoma patients.
However, preliminary data seem to indicate that a large variety of induced alterations may
drive resistance to BRAF inhibitors: upregulation of the receptor tyrosine kinase (RTK) effec‐
tors [99], mutation in NRAS gene and platelet-derived growth factor receptor β (PDGFRβ)
[99], amplification of the CCND1/Cyclin D1 gene or lack of phosphatase-and-tensin homo‐
logue (PTEN) function [100], mutations in downstream MEK gene [101], activation of MAPK
pathway agonists such as COT kinase [102], or enhancement of the IGF-1R/PI3K signaling
[103]. These findings highlight the need for combination therapy.
The MEK inhibitors (AS703026, E6201, GSK1120212, GDC0973, MEK162) as single agents
have activity against melanoma, in patients either carrying BRAF mutations and unexposed
to prior BRAF inhibitor therapy or presenting NRAS mutations [30]. A new combination of
MEK and BRAF inhibitors as first line therapy for BRAF mutated melanoma patients naïve
to prior anti-BRAF treatment is showing great promise [30].
The BRAF mutations may coexist with additional molecular alterations, with subsequent
constitution of further biological and molecular subgroups of melanoma patients:
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a. Impairment of the p16CDKN2A-CDK4/CCND1-RB or p14CDKN2A-MDM2-TP53 pathways,
with reduced expression of the p16CDKN2A protein and tendency to amplification of the
CDK4/CCND1 gene loci or inactivation of the TP53 gene (with consequent functional
loss of the p53 protein), respectively. This subtype benefits by the treatment with inhibi‐
tors of the cyclin-dependent kinases.
Melanoma patients carrying genetic alterations affecting p16CDKN2A could potentially be
treated with inhibitors of CDK4/CDK6. There are currently no validated therapeutic options
for melanoma with mutated p14CDKN2A. Conversely, several CDK4 inhibitors (Alvocidib,
AT-7519, P1446A-05, PD-0332991, Flavopiridol/alvocidib/HMR 1275, P276-00, R547,
SNS-032/ BMS-387032, UCN-01, ZK 304709/MTGI) are currently under investigation for a
variety of cancer types, including metastatic melanoma, and results are awaited. For p53,
there are currently no drugs, approved or in trials, against such a target. Conversely, an an‐
ti-sense agent (Oblimersen) targeted at nuclear Bcl-2 has been evaluated in trials, failing to
demonstrate a significant clinical benefit among patients with melanoma [104].
b. Amplification of MITF ± associated with reduction of the protein expression levels.
No drug targeting MITF has been developed; however, expression of MITF has been dem‐
onstrated to be reduced by compounds inhibiting the multiple histone deacetylase (HDAC)
complex [105]. Ongoing trials based on HDAC-inhibitors [LBH589 (Panobinostat) or Valpro‐
ic acid (Vorinostat)] will elucidate whether a clinical benefit could be obtained by down-reg‐
ulating intracellular level of MITF protein.
c. Activation of NF-kB.
Proteasome inhibitors, such as Bortezomib (Velcade, previously known as PS-341), represent
a new class of anticancer therapeutic agents which inhibit degradation of important cell cy‐
cle and/or regulatory proteins, including IkB [106-107]. Bortezomid has been demonstrated
to contribute in maintaining integrity of the complexes sequestering NF-kB into the cyto‐
plasm, thus reducing the NF-kB activity [106-107]. Phase 2 studies combinating Bortezomib
with other chemotherapeutic agents, including paclitaxel, carboplatin, or temozolomide
equally have been established [108-109]. A compound that more directly targets the NF-kB
pathway is BMS-345541 (4(2'-aminoethyl) amino-1,8-dimethylimidazo(1,2-a)quinoxaline),
identified as a selective inhibitor of the catalytic subunits of IKK that binds at an allosteric
site of the enzyme [110].
Since mutational activation of BRAF in human melanomas has been demonstrated to con‐
tribute to constitutive induction of NF-kB activity through an increase of the IKK activity
[111], inhibition of BRAF signaling using the above mentioned inhibitors may decrease the
NF-kB transcriptional activity and sensitize melanoma cells to apoptosis.
2. Subtype NRAS
Prevalence of NRAS mutation, with markedly increased expression level of activated ERK
(phospoERK1-2) and eventual activation of AKT. This subtype benefits by the treatment with
inhibitors of MEK or mTORC.
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To date, two approaches have been considered in developing drugs against RAS. The first is
based on the block of farnesylation. A small clinical trial using an inhibitor of the farnesyl
transferase enzyme failed to be efficacious in a melanoma cohort; however, patients includ‐
ed into such a study were not selected on the basis of their NRAS mutation status [112-113].
In the light of recent successes of the target therapies based on anti-BRAF or anti-cKIT inhib‐
itors, a more stringently selected cohort carrying alterations in NRAS gene would have in‐
creased responsiveness. On the other hand, a direct targeting of RAS has been demonstrated
to be very difficult [114]; this is the reason why therapeutic strategies have focused on inhib‐
iting downstream effectors into the pathways activated by RAS (i.e., MEK inhibitors for the
MAPK pathway - see above - and mTORC inhibitors for the PI3K-AKT pathway - see be‐
low), which represent the second treatment approach against RAS.
3. Subtype cKIT
Prevalence of cKIT mutations ± gene amplification and/or increased protein expression lev‐
els. This subtype benefits by the treatment with inhibitors of cKIT (in particular, patients
carrying gene mutations, with some sequence variants - such as K642E e L576P - which are
highly responsive).
Activating cKIT mutations have been implicated in a variety of cancers, mainly represented
by gastrointestinal stromal tumors (GIST) and chronic myelogenous leukemia (CML). This
is the reason why several drugs targeting cKIT have been developed and tested in clinical
trials, including Imatinib (approved for Philadelphia chromosome–positive CML and cKIT-
positive GIST) and Sunitib (approved for advanced kidney cancer and Imatinib-resistant
GIST) as well as Nilotinib and Dasatinib (approved for CML and Philadelphia chromosome-
positive acute lymphoblastic leukemia).
The inhibitors of cKIT that may have a therapeutic benefit in melanoma, by inducing cell cy‐
cle arrest and apoptosis as well as significantly inhibiting cell migration and invasion of tu‐
mor cells, are:
Imatinib mesylate, formerly known as STI571, is designated chemically as 4-benzamide
methanesulfonate. The efficacy of imatinib varies with the site of cKIT mutation; moreover,
this drug can inhibit both the wild-type receptor activated by ligand and mutated receptor
in the absence of ligand. However, imatinib is less effective at inhibiting the receptor with
mutations in the enzymatic site (exon 17 mutations) [79];
Nilotinib (AMN107), which has been rationally designed based on the imatinib mesylate
scaffold to have a more selective action. On this regard, Nilotinib inhibits both wild-type
and cKIT mutants in exon 11 (V560del and V560G), exon 13 (K642E), double mutants in‐
volving exons 11,  13,  and 17 as well  as imatinib-resistant cKIT mutant (V560del/V654A)
cells [115];
Dasatinib, which is a piperazinyl ethanol exhibiting increased potency but reduced selectivi‐
ty compared with imatinib mesylate, has been demonstrated to inhibit both wild type and
mutant cKIT in a dose-dependent manner, causing inhibition of cell migration and invasion
through reduction of the phosphorylation of either Src kinase and FAK pathway [116-117].
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4. Subtype mTORC
Prevalence of PTEN loss (± PI3K mutations, which are mostly infrequent) and phosphoryla‐
tion of AKT, with absence of concurrent mutations in BRAF gene. This subtype mainly bene‐
fits by the treatment with inhibitors of mTOR.
In melanoma cells, three potential targets may be considered for therapeutic intervention
against this pathway: AKT, PI3K and mTOR. Restoration of functional PTEN or interfering
with AKT and PI3K activity would increase chemosensitivity to apoptotic agents and im‐
prove the efficacy of anti-tumor treatment. Several inhibitors of PI3K (BKM120, BEZ235,
BGT226, GDC0941, PX-866, SF1126, and XL147) and AKT (GSK690693, MK2206, and
VQD-002) have been developed; results of ongoing trials are thus awaited. To date, clinical
trials using agents against the PI3K/AKT pathway have failed to demonstrate significant ef‐
ficacy [118]. However, one therapeutic approach which seems to inhibit this pathway is
based on the use of mTOR inhibitors [119]: rapamycin, Temsirolimus (CCI-779), Everolimus
(RAD001), Sirolimus and AZD8055. While controversial data have been reported for rapa‐
mycin (suppressing disease progression in some patients with glioblastoma but ineffective
in controlling the disease in others) [120], a limited advantage in response rates has been so
far described for Temsirolimus [121]. It is to be underlined that none of the trials with mTOR
inhibitors included patients specifically selected for alterations in the AKT/PI3K pathway.
Several clinical trials are investigating specific combinations of mTOR inhibitors and chemo‐
therapy drugs in the treatment of melanoma.
5. Subtype GNAQ/GNA11
Prevalence of GNAQ/GNA11 mutations, with increased expression level of phosphoERK.
This subtype benefits by the treatment with inhibitors of MEK.
The GNAQ and GNA11 genes encodes specific GTP binding proteins that mediate signal
transduction from the inner cell surface to the MAPK pathway through activation of the
protein kinase C (PKC) enzyme [122]. Somatic mutations in GNAQ gene have been observed
in about 90% of blue naevi, 50% of malignant blue naevi and 50% of primary uveal melano‐
ma; conversely, the GNA11 mutations have been found in less than 10% of blue nevi, about
one third of primary uveal melanomas, and about 60% of metastatic uveal melanoma [122].
Since mutations in these two genes have non been detected among all the remaining types
of melanoma (cutaneous, acral, mucosal), a clinical trial aimed at testing efficacy of a MEK
inhibitor, Dabrafenib/GSK1120212, has been focused on patients with metastatic uveal mela‐
noma carrying GNAQ and/or GNA11 mutations [123].
4. Diagnostic panel of molecular alterations
The most prevalent molecular alterations within the heterogeneous patterns of biological
features which characterize the distinct subtypes of melanoma are here summarized, accord‐
ing to the anatomical site of melanoma onset, the degree of exposure to the sun, and the his‐
tologic characteristics of the tumor lesions.
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• Acral melanoma
Mutation ± amplification of cKIT; amplification of CDK4 or CCND1 (associated with in‐
creased expression levels of the related proteins); amplification of the 11q13, 22q11-13,
and/or 5p15 genomic loci.
• Melanoma of the head and neck district and melanoma on skin with chronic sun-induced
damage (CSD)
Amplification of CDK4 and/or CCND1; increased expression levels of p53 protein; mutation
± amplification of cKIT (in about 5% of cases).
• Melanoma of the trunk and melanoma on skin without chronic sun-induced damage
(non-CSD)
Mutation of BRAF or, alternatively, NRAS (with eventual coexistence of molecolar altera‐
tions which may ba associated with BRAF mutations; see above); tendency to reduced ex‐
pression of the p53 protein; occurrence of specific polymorphisms in MC1R gene.
• Mucosal melanoma
Mutation ±  amplification of  cKIT;  amplification of  CDK4  or  CCND1  (associated with in‐
creased expression levels of the related proteins); mutation of BRAF  (in less than 10% of
cases).
• Uveal melanoma
Mutation ± amplification of cKIT; mutation of GNAQ and/or GNA11.
Knowledge of the principal molecular alterations to be tested in patients with such distinct
subtypes of melanoma will be of great clinical importance, because it is likely to result in
separate targeted therapeutic approaches and prevention strategies. To date, it has been al‐
ready developed a panel of molecular tests to be performed in patients with melanoma from
different anatomical locations (Figure 3). This initial “flow-chart” will surely become more
detailed and enriched on the basis of the progressive identification and validation of addi‐
tional genetics and molecular alterations correlated with the disease.
Finally, recent meta-analyses tried to define the prognostic role of majority of molecular al‐
terations previously described [124-125]:
• negative prognostic factors
loss of p53; over-expression of iNOS, AP-2, MMP-2 and metallothioneine; increased prolifer‐
ation index (high expression levels of Ki-67);
• positive prognostic factors
reduced expression or loss of p16CDKN2A; over-expression of Bcl-2 and ATF-2 (± associated
with simultaneous increases expression of beta-catenin, fibronectin and p21 proteins).
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Figure 3. Principal genetic and molecular tests on tumor tissues for the different types of melanoma. Amp,
gene amplification detected by fluorescence in situ hybridization (FISH) analysis. Exp, protein expression level detected
by immunohistochemistry. Mut, gene sequence variation detected by mutation analysis. In red, tests for less prevalent
alterations.
5. Conclusion
Taken together all the described molecular mechanisms involved in melanoma genesis and
progression, data seem to emphasize the fact that in melanoma, but probably in all types of
cancer, it is unlikely that targeting a single component in the signalling pathway will yield
significant anti-tumour responses. For this purpose, molecular analyses could help clinicians
to define the prognosis (prognostic value) as well as to make a prediction, identifying the
subsets of patients who would be expected to be more or less likely to respond to specific
therapeutic interventions (predictive value).
In other words, it is becoming evident that combination therapies targeting simultaneously
several signaling pathways might be a winning therapeutic strategy to treat melanoma pa‐
tients. Preclinical studies using combination of anti BRAF and AKT3 siRNA demonstrated a
significantly higher reduction of tumor growth compared to single agent administration
[126-127]. There is also evidence of synergism among MEK and PI3K inhibitors as well as
promising results have been obtained by combinations of the mTOR inhibitors and sorafe‐
nib or MEK inhibitors [121, 128-129]. In contrast to single agent activity, these combinations
of target drugs resulted in recovering of apoptosis by complete down-regulation of the anti-
apoptotic proteins Bcl-2 and Mcl-1. Cooperation between BRAF and MEK inhibitors has also
been demonstrated in preclinical studies with a consistent increase of apoptosis and abroga‐
tion of ERK activation compared to BRAF inhibitor alone [130]. Such cooperation was based
on the observation that MEK activation was not abrogated in melanoma cells that develop
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resistance to BRAF inhibitors [131-134]. BRAF and MEK targeted synergic therapy is cur‐
rently tested in a phase I clinical trial (NCT01072175) which combines the selective RAF in‐
hibitor GSK2118436 with the MEK inhibitor GSK1120212 in patients with BRAF mutant
tumors [135].
After decades without perspective, the history of medical treatment for the advanced mela‐
noma is rapidly changing. Combined therapeutic approaches do represent the next chal‐
lenge for treatment of patients with such a disease.
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